Journal of Cancer Research and Therapeutics Close
 

Table 1: Evaluation of suppression of viability (IC50) of primary human endometrial cells treated with doxorubicin, cisplatin, and recombinant analog of lactaptin RL2

Table 1: Evaluation of suppression of viability (IC<sub>50</sub>) of primary human endometrial cells treated with doxorubicin, cisplatin, and recombinant analog of lactaptin RL2